The stop-work order on U.S.A.I.D.-funded research has left thousands of people with experimental drugs and devices in their ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

In parallel with clinical advancements ... the comprehensive Pro Research Report available exclusively on InvestingPro, covering detailed analysis of BTAI's financial health and growth prospects.

Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of ...

The above supports a framework in which pragmatic designs can be the underpinnings of clinical trials in low-resource settings. The following represents disclosure information provided by authors of ...

Clinical data for AlphaVac and NanoKnife were ... helped by a reduction in R&D as key trials completed, while sales and marketing expense was flat and G&A expense rose about 12%.

In parallel with clinical advancements ... seeking deeper insights can access the comprehensive Pro Research Report available exclusively on InvestingPro, covering detailed analysis of BTAI's ...

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), an immunotherapy company specializing in engineered T cell therapeutics, has announced a series of strategic moves aimed at ...

Previously, James worked as a Research Analyst at Saidler & Co ... flows to analyze Bitcoin's role within the broader financial system. In addition to his professional endeavors, James serves ...

A recent Sg2 analysis of inpatient dialysis care finds that for some hospitals currently operating in-house dialysis services, outsourcing may offer clinical, operational and financial benefits ...